| Date | Upside/Downside | Analyst Firm | Price Target Change | Rating Change | Previous / Current Rating |
|---|---|---|---|---|---|
| 10/09/2023 | 69.09% | JP Morgan | $58 → $57 | Maintains | Overweight |
| 09/27/2023 | 36.46% | Canaccord Genuity | → $46 | Initiates Coverage On | → Buy |
| 09/14/2023 | 42.39% | Cantor Fitzgerald | $45 → $48 | Maintains | Overweight |
| 08/11/2023 | 54.26% | Truist Securities | $48 → $52 | Maintains | Buy |
| 08/04/2023 | 48.32% | Keybanc | $45 → $50 | Maintains | Overweight |
| 05/22/2023 | 48.32% | BTIG | → $50 | Initiates Coverage On | → Buy |
| 05/15/2023 | 72.06% | JP Morgan | $61 → $58 | Maintains | Overweight |
| 05/09/2023 | 48.32% | B of A Securities | $40 → $50 | Maintains | Buy |
| 05/09/2023 | 33.49% | Cantor Fitzgerald | $44 → $45 | Maintains | Overweight |
| 04/21/2023 | 30.53% | Cantor Fitzgerald | → $44 | Initiates Coverage On | → Overweight |
| 01/05/2023 | 0.86% | SVB Leerink | $59 → $34 | Downgrades | Outperform → Market Perform |
| 12/19/2022 | 33.49% | Keybanc | $55 → $45 | Maintains | Overweight |
| 11/18/2022 | 83.92% | JP Morgan | $78 → $62 | Maintains | Overweight |
| 09/16/2022 | 63.16% | Keybanc | → $55 | Maintains | Overweight |
| 09/07/2022 | 66.12% | Truist Securities | → $56 | Initiates Coverage On | → Buy |
| 12/02/2021 | 77.99% | Jefferies | → $60 | Initiates Coverage On | → Buy |
| 09/30/2021 | 140.28% | Berenberg | → $81 | Initiates Coverage On | → Buy |
| 09/28/2021 | 137.32% | Barclays | $72 → $80 | Maintains | Overweight |
| 08/25/2021 | 113.59% | Barclays | $64 → $72 | Maintains | Overweight |
| 08/12/2021 | 89.85% | Barclays | → $64 | Initiates Coverage On | → Overweight |
| 08/06/2021 | 75.02% | SVB Leerink | $64 → $59 | Maintains | Outperform |
| 06/02/2021 | — | Guggenheim | Downgrades | Buy → Neutral | |
| 05/07/2021 | 89.85% | SVB Leerink | $58 → $64 | Maintains | Outperform |
| 03/10/2021 | — | B of A Securities | Upgrades | Neutral → Buy | |
| 11/25/2020 | 3.83% | B of A Securities | $30 → $35 | Maintains | Neutral |
| 11/06/2020 | 48.32% | SVB Leerink | $44 → $50 | Maintains | Outperform |
| 08/24/2020 | 3.83% | JP Morgan | $30 → $35 | Maintains | Overweight |
| 08/06/2020 | -2.11% | Piper Sandler | $32 → $33 | Maintains | Overweight |
| 08/06/2020 | 30.53% | SVB Leerink | $35 → $44 | Maintains | Outperform |
| 08/06/2020 | -5.07% | Citigroup | $28 → $32 | Maintains | Buy |
| 07/27/2020 | -16.94% | B of A Securities | $26 → $28 | Maintains | Neutral |
| 07/01/2020 | 3.83% | SVB Leerink | → $35 | Initiates Coverage On | → Outperform |
| 06/02/2020 | -11.01% | Guggenheim | → $30 | Initiates Coverage On | → Buy |
| 05/13/2020 | -16.94% | Citigroup | $29 → $28 | Maintains | Buy |
| 03/10/2020 | -13.97% | Citigroup | $30 → $29 | Maintains | Buy |
| 12/04/2019 | -16.94% | B of A Securities | $26 → $28 | Reiterates | → Neutral |
| 11/19/2019 | -22.87% | JP Morgan | → $26 | Initiates Coverage On | → Overweight |
| 11/19/2019 | -16.94% | SVB Leerink | → $28 | Initiates Coverage On | → Outperform |
| 11/19/2019 | -11.01% | Citigroup | → $30 | Initiates Coverage On | → Buy |
| 11/19/2019 | -2.11% | Piper Sandler | → $33 | Initiates Coverage On | → Overweight |
What is the target price for Progyny (PGNY)?
The latest price target for Progyny (NASDAQ: PGNY) was reported by JP Morgan on October 9, 2023. The analyst firm set a price target for $57.00 expecting PGNY to rise to within 12 months (a possible 69.09% upside). 13 analyst firms have reported ratings in the last year.
What is the most recent analyst rating for Progyny (PGNY)?
The latest analyst rating for Progyny (NASDAQ: PGNY) was provided by JP Morgan, and Progyny maintained their overweight rating.
When is the next analyst rating going to be posted or updated for Progyny (PGNY)?
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Progyny, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Progyny was filed on October 9, 2023 so you should expect the next rating to be made available sometime around October 9, 2024.
Is the Analyst Rating Progyny (PGNY) correct?
While ratings are subjective and will change, the latest Progyny (PGNY) rating was a maintained with a price target of $58.00 to $57.00. The current price Progyny (PGNY) is trading at is $33.71, which is out of the analyst's predicted range.